Discovery of tricyclic HIV-1 integrase-LEDGF/p75 allosteric inhibitors by intramolecular direct arylation reaction.
Taoda, Y., Akiyama, T., Tomita, K., Fujiwara-Kitamura, M., Tamura, Y., Kawasuji, T., Matsuoka, E., Akihisa, E., Seki, T., Yoshinaga, T.(2022) Bioorg Med Chem Lett 64: 128664-128664
- PubMed: 35272008 
- DOI: https://doi.org/10.1016/j.bmcl.2022.128664
- Primary Citation of Related Structures:  
7WCE - PubMed Abstract: 
We have been conducting exploratory research to develop human immunodeficiency virus type-1 (HIV-1) integrase-LEDGF/p75 allosteric inhibitors (INLAIs). Here, we report on a newly designed compound with a tricyclic scaffold that shows promise as an inhibitor. Various scaffolds were synthesized by intramolecular direct arylation reaction to fix the position of a lipophilic side chain required for antiviral activity. Among these, the compound having an N-mesyl dihydrophenanthridine ring showed the best antiviral activity. Compound 42i, prepared by side chain optimization of the C-4 and C-6 positions, exhibited high antiviral activity against wild-type (WT) and the T174I mutant (EC 50 (WT) = 4.6 nM, EC 50 (T174I) = 83 nM) with a good PK profile. Based on co-crystal structural analysis of compound 42i and WT HIV-1 IN CCD, we discuss the interaction important for high antiviral activity.
Organizational Affiliation: 
Shionogi Pharmaceutical Research Center, Shionogi & Company, Limited, 1-1, Futabacho, 3-chome, Toyonaka 561-0825, Japan. Electronic address: yoshiyuki.taoda@shionogi.co.jp.